|
 Investor
Relations
CEO Message
To Our Stockholders:
The past year was a significant one for The Quigley Corporation.
The COLD-EEZE® franchise, with two brand extensions, continued to
demonstrate strength in a highly competitive market. And Quigley
Pharma, our pharmaceutical R&D business, made great progress
in the development of QR-333 for diabetic peripheral neuropathy.
We don't feel the need to limit ourselves to a single product category. We do,
however, insist that our solutions meet two important criteria: that they be
derived from botanical or other natural sources and that they address a
genuine consumer need.
To that end, The Quigley Corporation has been self-funding its pharmaceutical
research since 2001. While the Company's annual investment in R&D seems
significant, it remains aligned with industry expectations. The majority of large
pharmaceutical companies invest approximately 15 percent of their net sales
on research and development expenses. In 2007, The Quigley Corporation
invested 16.4 percent.
Ultimately, this is not about reinvestment. It's about reinvention. And at The
Quigley Corporation, we are committed to driving our business forward, to
maintaining our position as one of the world's premier natural health medical
science companies, and to delivering value to our customers and stockholders.
I invite you to read more about our efforts and our successes in 2007, and I
thank you for your ongoing support.
Guy J. Quigley
President, Chairman & Chief Executive Officer
FORWARD-LOOKING STATEMENTS
In addition to historical information, this Webpage contains forward-looking
statements. These forward-looking statements are subject to certain risks and
uncertainties that could cause actual results to differ materially from those
reflected in these forward-looking statements. Factors that might cause such a
difference include, but are not limited to, management of growth, competition,
pricing pressures on the Company’s product, industry growth and general
economic conditions. Readers are cautioned not to place undue reliance on these
forward-looking statements, which reflect management’s opinions only as
of the date hereof. The Company undertakes no obligation to revise or publicly
release the results of any revision to these forward-looking
statements.
CERTAIN RISK FACTORS
The Quigley Corporation makes no representation that the U.S. Food and Drug
Administration or any other regulatory agency will grant an Investigational New
Drug (“IND”) or take any other action to allow its formulations to
be studied or marketed. Furthermore, no claim is made that potential medicine
discussed herein is safe, effective, or approved by the Food and Drug
Administration. Additionally, data that demonstrates activity or effectiveness
in animals or in-vitro tests do not necessarily mean the formula test compound,
referenced herein will be effective in humans. Safety and effectiveness in
humans will have to be demonstrated by means of adequate and well controlled
clinical studies before the clinical significance of the formula test compound
is known. Readers should carefully review the risk factors described in other
sections of the filing as well as in other documents the Company files from
time to time with the Securities and Exchange Commission.
|
